A panel of advisers to the U.S. Food and Drug Administration has unanimously recommended approval of a new flu vaccine developed by Moderna, specifically for adults who are 50 years of age or older.
The vote took place on Thursday, with all nine panel members agreeing that the vaccine’s benefits outweigh its potential risks. The advisory board supported the use of the shot across two age groups — adults ranging from 50 to 64 years old, as well as those aged 65 and above.
